MedTrace Logo

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

NCT06304545 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-03-12

No results posted yet for this study

Summary

This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal cancer requiring anus preservation.

Conditions

Interventions

DRUG

Camrelizumab

Camrelizumab IV 200mg

DRUG

Chemotherapy

Capecitabine PO oxaliplatin IV

RADIATION

Radiotherapy

Radiotherapy 50Gy /45Gy /25 fractions

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Chunbo Zhao, MD · Harbin Medical University Cancer Hosptital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-08-16
Completion
2027-03-15

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06304545 on ClinicalTrials.gov